Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.048
Neutral
RSI(14)
31.313
Neutral
STOCH(KDJ)(9,3,3)
15.627
Sell
ATR(14)
0.149
High Vlolatility
CCI(14)
-83.973
Neutral
Williams %R
75.472
Sell
TRIX(12,20)
-2.373
Sell
StochRSI(14)
0.000
Oversold
Search
Grace Therapeutics, Inc
GRCEAdd to Watchlist
2.160USD
-0.030-1.37%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
33.42MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Grace Therapeutics, Inc
Currency: USD Updated: 2026-05-15Key Insights
Grace Therapeutics, Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 117 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Grace Therapeutics, Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Grace Therapeutics, Inc Highlights
StrengthsRisks
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Undervalued
The company’s latest PE is -6.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.68M shares, decreasing 3.98% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 129.78K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.84.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+173.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Grace Therapeutics, Inc is 5.63, ranking 334 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
4.15
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.67
Operational Efficiency
2.66
Growth Potential
6.79
Shareholder Returns
6.87
Grace Therapeutics, Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Grace Therapeutics, Inc is 7.63, ranking 91 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.93, which is -95.85% below the recent high of -0.29 and -137.50% above the recent low of -16.47.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 117/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Grace Therapeutics, Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+173.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Grace Therapeutics, Inc
GRCE
2
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Grace Therapeutics, Inc is 6.88, ranking 131 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.22 and the support level at 0.95, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.256
Sell
MA10
2.293
Sell
MA20
2.604
Sell
MA50
3.597
Sell
MA100
3.652
Sell
MA200
3.393
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Grace Therapeutics, Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.76%, representing a quarter-over-quarter decrease of 1.62%. The largest institutional shareholder is James Simons, holding a total of 129.78K shares, representing 0.84% of shares outstanding, with 101.61% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Grace Therapeutics, Inc is 4.50, ranking 79 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.31
VaR
+6.47%
240-Day Maximum Drawdown
+59.06%
240-Day Volatility
+94.02%
Return
Best Daily Return
60 days
+12.04%
120 days
+12.04%
5 years
+52.25%
Worst Daily Return
60 days
-45.48%
120 days
-45.48%
5 years
-45.48%
Sharpe Ratio
60 days
-1.23
120 days
-0.25
5 years
-0.33
Risk Assessment
Maximum Drawdown
240 days
+59.06%
3 years
+60.00%
5 years
+92.24%
Return-to-Drawdown Ratio
240 days
-0.39
3 years
-0.17
5 years
-0.20
Skewness
240 days
-4.59
3 years
+0.08
5 years
+1.33
Volatility
Realised Volatility
240 days
+94.02%
5 years
+159.59%
Standardised True Range
240 days
+9.74%
5 years
+14.65%
Downside Risk-Adjusted Return
120 days
-20.61%
240 days
-20.61%
Maximum Daily Upside Volatility
60 days
+66.26%
Maximum Daily Downside Volatility
60 days
+146.40%
Liquidity
Average Turnover Rate
60 days
+5.69%
120 days
+3.18%
5 years
--
Turnover Deviation
20 days
+571.71%
60 days
+398.94%
120 days
+179.21%
Peer Comparison
Biotechnology & Medical Research
Grace Therapeutics, Inc
GRCE
6.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
